Company signals · Biotech & Pharma
Neurocrine Biosciences
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: MitchelLake's Talent Market Index sits at 111.2 (Hot), up 5.2 on the prior month; Americas hiring signal is running rising (+6.3pts).
Neurocrine Biosciences: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 24 tracked companies.
Signals at Neurocrine Biosciences
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Ma Activity · Americas
Biogen →Biogen announced and closed acquisition of Apellis Pharmaceuticals (immunology and rare diseases) in May 2026, and has just announced a second acquisition of an undisclosed company for $1 billion.
Intelligence powered by Autonodal ↗